


AMENDMENT TO THE SPECIFICATION

Please replace the Abstract with the following substitute Abstract:

----- ABSTRACT







Selective MMP-13 inhibitors are fused pyrimidinones of the formula



or a pharmaceutically acceptable salt thereof,

wherein:

W, together with the carbon atoms to which it is attached, form a 5-membered ring diradical



wherein Y, R¹, R⁴, X, A, B, R², and R³ are as defined for Formula I in the

specification; X is O, S, SO, SO₂, NR⁵, or CH₂;

⊖ (O)_n

⊥ ⊥

A is C or S;

B is O or NR⁵; or

A and B are taken together to form C≡C;

R¹, R⁴, and R⁵ are hydrogen, alkyl, alkenyl, alkynyl, (CH₂)_n aryl, (CH₂)_n

cycloalkyl, C₁-C₆ alkanoyl, or (CH₂)_n heteroaryl;

R² and R³ are hydrogen, alkyl, alkenyl, alkynyl CN, NO₂, NR⁴R⁵, (CH₂)_n

cycloalkyl, (CH₂)_n aryl, or (CH₂)_n heteroaryl;

R² may further be halo;

n is an integer of from 0 to 5; and

R⁴ and R⁵ when taken together with a nitrogen to which they are both attached complete a 3 to 8 membered ring containing carbon atoms and optionally containing O, S, or N, and substituted or unsubstituted;

with the proviso that R¹ and R³ are not both selected from hydrogen and C₁-C₆ alkyl. -----